Yumanity Therapeutics (FRA:8IY) Short-Term Capital Lease Obligation : €0.21 Mil (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Short-Term Capital Lease Obligation?

Yumanity Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.21 Mil.

Yumanity Therapeutics's quarterly Short-Term Capital Lease Obligation declined from Mar. 2022 (€0.55 Mil) to Jun. 2022 (€0.53 Mil) and declined from Jun. 2022 (€0.53 Mil) to Sep. 2022 (€0.21 Mil).

Yumanity Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2019 (€0.57 Mil) to Dec. 2020 (€3.81 Mil) and increased from Dec. 2020 (€3.81 Mil) to Dec. 2021 (€4.52 Mil).

Yumanity Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Yumanity Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Short-Term Capital Lease Obligation Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Short-Term Capital Lease Obligation

0.57

3.81

4.52

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial							4.23	4.52	0.55	0.53	0.21

Yumanity Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Yumanity Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines